Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 10, 2014, Pages 1159-1165

  Gupta, S ^a   Abimbola, T ^b   Date, A ^b   Suthar, A B ^c   Bennett, R ^d   Sangrujee, N ^b   Granich, R ^a  

^a UNAIDS   (Switzerland)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d Independent Consultant   (United Kingdom)

Author keywords

Economic analysis; Intensified TB case finding; Isoniazid; Xpert MTB RIF

Indexed keywords

ANTIRETROVIRUS AGENT; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ALGORITHM; ARTICLE; ASSAY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COMMUNITY LIVING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS ASSAY; PATIENT ASSESSMENT; RESISTANCE TO RIFAMPICIN ASSAY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; STATISTICAL MODEL; SYMPTOM; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; ANTIBIOTIC RESISTANCE; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; HIV INFECTIONS; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; RADIOGRAPHY;

ALGORITHMS; ANTITUBERCULAR AGENTS; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; DRUG RESISTANCE, BACTERIAL; HIV INFECTIONS; HUMANS; ISONIAZID; MODELS, ECONOMIC; MYCOBACTERIUM TUBERCULOSIS; RADIOGRAPHY; RIFAMPIN; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

EID: 84907163021     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.13.0571     Document Type: Article

References (33)

1. World Health Organization Global tuberculosis report, 2013 WHO/HTM/TB/2013.11 Geneva, Switzerland: WHO, 2013 http://apps.who.int/i r i s/b i t s tream/10665/91355/1/9789241564656-eng.pdf Accessed June 2014.
2. Joint U nited Nations Programme on HIV/AIDS UNAIDS report on the global AIDS epidemic 2013 UNAIDS/JC2502/1/E Geneva, Switzerland: UNAIDS, 2013 http://www.unaids org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-G lobal-Report-2013-en.pdf Accessed June 2014.
3. World Health Organization Policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders WHO/HTM/TB/2012.1 WHO/HIV/2012.1 Geneva, Swit zerland: WHO, 2012 http://whqlibdoc.who.int/publications/2012/9789241503006-eng.pdf Accessed June 2014.
4. Suthar A B, Lawn S D, del Amo J, et al Antiretroviral therapy for prevention of tuberculosis in a dults with HIV: a systematic review and meta-analysis PLOS MED 2012; 9: e1001270.
5. Middelkoop K, Bekker L G, Myer L, et al Antiretroviral therapy and TB notification rates in a high HIV preva lence South African community J Acquir Immune Defic Syndr 2011; 56: 263-269.
6. Miranda A, Morgan M, Jamal L, et al Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001 PLOS ONE 2007; 2: e826.
7. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents Geneva, Switzerland: WHO, 2010 http://whql ibdoc.who.int/publications/2010/9789241599764-eng.pdf Accessed June 2014.
8. World Health Organization Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a publ ic health approach Geneva, Switzerland: WHO, 2013 http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf Accessed June 2014.
9. World Health Organization Guidelines on intensified tuberculosis case findin g and isoniazid preventive therapy for people living with HIV in resource constrained setting Geneva, Switzerland: WHO, 2011 http://whqlibdoc.who.int/publications/2011/9789241500708-eng.pdf Accessed June 2014.
10. World Health Organization WHO policy on TB infection control in health-care facilities, congregate settings and households WHO/HTM/TB/2009.419 Geneva, Switzerland: WHO, 2009 http://whqlibdoc.who.int/publications/2009/978924159 8323-eng.pdf Accessed June 2014.
11. Joint United Nations Programme on HIV/AIDS UNAIDS Report on the Global AIDS Epidemic 2012 Geneva, Switzerland: UNAIDS, 2012 http://www.unaids.org/en/media/unaids/contentasse ts/documents/epidemiology/2012/gr2012/20121120-UNAIDS-Global-Report-2012-en.pdf Accessed June 2014.
12. Harries A D, Hargreaves N J, Gausi F, Kwanjana J H, Salaniponi F M.Preventing tuberculosis among health workers in Malawi Bull World Health Organ 2002; 80: 526-531.
13. Getahun H, KittikraisakW, Heilig CM, et al Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies PLoS Med 2011; 8: e1000391.
14. Shrestha R K, Mugisha B, Bunnell R, et al Cost-utility of tuberculosis prevention among HIV-infected adults in Kampala, Uganda Int J Tuberc Lung Dis 2007; 11: 747-754.
15. Lawn S D, Harries A D, Williams B G, et al Antiretroviral therapy and the control of HIV-associated tuberculosis Will ART do it? Int J Tuberc Lung Dis 2011; 15: 571-581.
16. Akolo C, Adetifa I, Shepperd S, Volmink J.Treatment of latent tuberculosis infection in HIV-infected persons Cochrane Database Syst Rev 2010(1): CD000171.
17. Samandari T, Agizew T B, Nyirenda S, et al 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial Lancet 201 1; 377: 1588-1598.
18. Basu S, Andrews J R, Poolman E M, et al Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study Lancet 2007; 370: 1500-1507.
19. Monkongdee P, McCarthy K D, Cain K P, et al Yield of acidfast smear and mycobacterial culture for tuberculosis diagnosis in people with human im munodeficiency virus Am J Respir Crit Care Med 2009; 180: 903-908.
20. Cain K P, McCarthy K D, Heilig C M, et al An algorithm for tuberculosis screening and diagnosis in people with HIV N Engl J Med 2010; 362: 707-716.
21. Lawn S D, Brooks S V, Kranzer K, et al Screening for HIVassociated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assa y: a prospective study PLOS MED 2011; 8: e1001067.
22. Boehme C C, Nicol M P, Nabeta P, et al Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study Lancet 2011; 377: 1495-1505.
23. Rangaka M X, Diwakar L, Seldon R, et al Clinical, immunological, and epidemiological importance of anti-tuberculosis T-cell responses in HIV-infected Africans Clin Infect Dis 2007; 44: 1639-1646.
24. Kerkhoff A D, Kranzer K, Samandari T, et al Systematic review o f TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy PLOS ONE 2012; 7: e49928.
25. Vassall A, van Kampen S, Sohn H, et al Rapid d iagnosis of tuberculosis with the Xpert MTB/RIF assay in high-burden countries: a cost-effectiveness analysis PLOS MED 2011; 8: e1001120.
26. Fairall L, Bachmann M O, Zwarenstein M, et al Coste ffectiveness of educational outreach to primary care nurses to increase tuberculosis case detection and improve respiratory care: economic evaluation alongside a randomised trial Trop Med Int Health 2010; 15: 277-286.
27. Dowdy D W, O'Brien M A, Bishai D.Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis Int J Tuberc Lung Dis 2008; 12: 1021-1029.
28. World Health Organi zation CHOosing Interventions that are Cost Effective (WHO-CHOICE) Costs and prices Countryspecific unit costs 2008 Geneva, Switzerland: WHO, 2008 http://www.who.int/choice/country/country-specific/en/index html Accessed June 2014.
29. Arnold D T, Bentham L M, Jacob R P, Lilford R J, Girling A J.Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a compre hensively tested cohort BMC Fam Pract 2011; 12: 9.
30. Granich R, Kahn J G, Bennett R, et al Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effective ness 2011-2050 PLOS ONE 2012; 7: e30216.
31. Goldie S J, Yazdanpanah Y, Losina E, et al Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire N Engl J Med 2006; 355: 1141-1153.
32. Walensky R P, Ross E L, Kumarasamy N, et al Costeffectiveness of HIV treatment as prevention in serodiscordant couples N Engl J Med 2013; 369: 1715-1725.
33. Williams B G, Granich R, De Cock K M, Glaziou P, Sharma A, Dye C.Antiretroviral therapy for tuberculosis control in nine African countries Proc Natl Acad Sci USA 2010; 107: 19485-19489.